HS
ANAB icon

HighVista Strategies’s AnaptysBio ANAB Stock Holding History

HighVista Strategies’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,574
Closed -$522K – 144
2024
Q3 		$522K Buy
+15,574
New +$532K 0.18% 128
2023
Q3 		– Sell
-37,651
Closed -$766K – 135
2023
Q2 		$766K Buy
37,651
+12,432
+49% +$252K 0.35% 73
2023
Q1 		$549K Buy
25,219
+11,215
+80% +$273K 0.45% 69
2022
Q4 		$434K Sell
14,004
-22,983
-62% -$649K 0.26% 79
2022
Q3 		$944K Buy
36,987
+3,884
+12% +$91K 0.54% 44
2022
Q2 		$672K Buy
33,103
+19,105
+136% +$423K 0.41% 58
2022
Q1 		$346K Buy
+13,998
New +$424K 0.22% 85

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

HighVista Strategies's ANAB Position: Q4 2024 in Review

HighVista Strategies sold out of AnaptysBio (ANAB) in Q4 2024, closing a stake of 15,574 shares — an estimated $522K sold.

HighVista Strategies first reported a position in ANAB in Q1 2022 and held it in 7 quarters. The position peaked at $944K in Q3 2022. 135 funds tracked by Wall St. Rank hold ANAB as of Q4 2024.

  • HighVista Strategies reported no remaining AnaptysBio position as of Q4 2024 after selling out during the quarter.
  • HighVista Strategies sold 15,574 AnaptysBio shares in Q4 2024, an estimated $522K.
  • HighVista Strategies first reported a position in AnaptysBio in Q1 2022 and held it in 7 quarters.
  • HighVista Strategies's AnaptysBio position peaked at $944K in Q3 2022.
  • 135 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2024.

Based on HighVista Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.